Stockscreener 앱 받기
57.17
1.74%
0.98
시간 외 거래:
57.88
0.71
+1.24%
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader
Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN
BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga
Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com
Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Marin Awareness Walk Draws Over 100 Community Members - Patch
inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria
inozyme pharma announces executive bonuses amid merger plans - Investing.com
BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews
The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com
Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail
FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma
Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India
Stifel maintains Buy on BioMarin, price target at $91 - Investing.com
Phenylktonuria Treatment Market Overall Study Report - openPR.com
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media
BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire
6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World
BioMarin agrees to acquire Inozyme for $270m - MSN
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus
Is this European biotech’s moment? — a BioCentury podcast - biocentury.com
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia
Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria
BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News
1.45%
0.86%
자본화:
|
볼륨(24시간):